Cuur Health

ALERT
When outdoor temperatures reach 1050 our mobile COVID-19 testing site closes for the day to ensure the safety of our medical staff. Thank you for your understanding.
Cuando las temperaturas exteriores alcanzan los 105 grados Nuestra prueba de COVID-19 móvil está cerrada durante el día para garantizar la seguridad de nuestro personal médico. Gracias por su comprensión.
Sexually Transmitted Infections (STI) Panel

SEXUALLY TRANSMITTED INFECTIONS (STI) PANEL

CUUR HEALTH is dedicated to maintaining the largest data set of infectious disease targets available in the world.

Sexually transmitted infections (STIs) are a public health problem, and their prevalence is only rising. It’s critical for diagnostic tests for STIs to not only aid the diagnosis of typical cases, but also atypical cases, asymptomatic infections and also multiple infections. Unfortunately, the existing diagnostic methods for STIs are fraught with several challenges, including delay in results, lack of sensitivity and specificity. CUUR HEALTH methods fulfill the criteria of accuracy, affordability, accessibility, efficiency, sensitivity, specificity and ease of handling. Results are rapid, cost-effective and reliable; offering increased sensitivity, specificity and speed. CUUR HEALTH methods are especially useful for microorganisms that cannot be or are difficult to cultivate by increasing automation and standardization and decreasing potential for human error.

Helix DNA
TARGETS
UTI Gram Positive Bacteria 
BacteriaE. faecalis
BacteriaE. faecium
BacteriaS. saprophyticus
BacteriaS. agalactiae
UTI Gram Negative Bacteria 
BacteriaA. baumannii
BacteriaC. freundii
BacteriaE. cloacae
BacteriaE. coli
BacteriaK. oxytoca
BacteriaK. pneumoniae
BacteriaM. morganii
BacteriaP. mirabilis
BacteriaP. vulgaris
BacteriaP. stuartii
BacteriaP. aeruginosa
UTI Fungal 
YeastC. albicans
Infectious Disease Care
STATISTICALLY SPEAKING
  • 2.3 million cases of chlamydia, gonorrhea and syphilis reported to CDC for 2017 and represents just a small fraction of the true disease burden
  • The total estimated direct cost of STIs annually in the U.S. about $16 billion